Trial Profile

An efficacy and safety study of Pixavir

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jul 2025 New trial record
20 Jun 2025 According to the TaiGen Biotechnology Media Release, the company announced on the evening of the 19th that it received a notice from its partner Jianxingyuan Pharmaceutical Group that the new influenza antiviral drug Pixavir marboxil (TG-1000) has passed the clinical trial review (IND) of pediatric dosage forms of the National Medical Products Administration (NMPA) of Chinese mainland and will start clinical trials soon.
20 Jun 2025 According to the TaiGen Biotechnology Media Release, efficacy and safety trial planned for Q4 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com